Francesca Zappacosta

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacology +7

Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases

Qi-An Sun, Yalin Wu, Francesca Zappacosta et al. · Journal of Biological Chemistry · 1999 · 327 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Cell Cycle Regulation of Myosin-V by Calcium/Calmodulin-Dependent Protein Kinase II

Ryan L. Karcher, Joseph T. Roland, Francesca Zappacosta et al. · Science · 2001 · 152 citations

Life Sciences, Biochemistry, Cell Biology +17

Single‐step purification and structural characterization of human interleukin‐6 produced in <i>Esherichia coli</i> From a T7 RNA polymerase expression vector

Rosaria Arcone, Piero Pucci, Francesca Zappacosta et al. · European Journal of Biochemistry · 1991 · 136 citations · Full text

Life Sciences, Immunology, Molecular Biology +14